AJP - Cell Physiology, Vol 273, Issue 2 C687-C702, Copyright © 1997 by American Physiological Society

ARTICLES

Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells

H. Kim, M. Barroso, R. Samanta, L. Greenberger and E. Sztul
Department of Cell Biology, University of Alabama, Birmingham School of Medicine 35294, USA.

The MDR-1 gene product, plasma membrane glycoprotein or P-glycoprotein (PGP), has been shown to confer drug resistance to cancer cells by acting as an energy-dependent drug-efflux pump. We have examined the endocytic traffic of PGP in human multidrug-resistant cells and tested whether the traffic and the steady-state intracellular localization of PGP can be experimentally modulated. Here we show that 1) under steady state approximately 70% of cellular PGP is on the surface whereas approximately 30% is intracellular, 2) surface PGP undergoes constitutive endocytosis and recycling, 3) endocytosis of PGP involves clathrin and adaptin complex 2-dependent mechanism, and 4) PGP cycles through a Rab5-responsive endosomal compartment. Biochemical (such as antibody crosslinking of PGP or treatment of cells with chloroquine) and molecular (such as overexpression of Rab5) treatments were used to modulate the endocytic/ recycling traffic of PGP. Such treatments resulted in the redistribution of PGP from the cell surface to intracellular compartments. Cells with such "mislocalized" PGP showed a decrease in multidrug resistance, suggesting that clinically relevant strategies can be attempted by modulating PGP's temporal and spatial distribution within cancer cells.

This article has been cited by other articles:

				I. Bottova, A. B. Hehl, S. Stefanic, G. Fabrias, J. Casas, E. Schraner, J. Pieters, and S. Sonda Host Cell P-glycoprotein Is Essential for Cholesterol Uptake and Replication of Toxoplasma gondii J. Biol. Chem., June 26, 2009; 284(26): 17438 - 17448. [Abstract] [Full Text] [PDF]

				O. Prokopenko and O. Mirochnitchenko Ischemia-reperfusion-inducible protein modulates cell sensitivity to anticancer drugs by regulating activity of efflux transporter Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1086 - C1097. [Abstract] [Full Text] [PDF]

				S. Ye, D. P. MacEachran, J. W. Hamilton, G. A. O'Toole, and B. A. Stanton Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif Am J Physiol Cell Physiol, September 1, 2008; 295(3): C807 - C818. [Abstract] [Full Text] [PDF]

				D. Fu and B. D. Roufogalis Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1543 - C1552. [Abstract] [Full Text] [PDF]

				J. Zhou, J. Yi, N. Hu, A. L. George Jr, and K. T. Murray Activation of Protein Kinase A Modulates Trafficking of the Human Cardiac Sodium Channel in Xenopus Oocytes Circ. Res., July 7, 2000; 87(1): 33 - 38. [Abstract] [Full Text] [PDF]

				G. D. Luker, K. R. Nilsson, D. F. Covey, and D. Piwnica-Worms Multidrug Resistance (MDR1) P-glycoprotein Enhances Esterification of Plasma Membrane Cholesterol J. Biol. Chem., March 12, 1999; 274(11): 6979 - 6991. [Abstract] [Full Text] [PDF]

				G. D. Luker, T. P. Flagg, Q. Sha, K. E. Luker, C. M. Pica, C. G. Nichols, and D. Piwnica-Worms MDR1 P-glycoprotein Reduces Influx of Substrates without Affecting Membrane Potential J. Biol. Chem., December 21, 2001; 276(52): 49053 - 49060. [Abstract] [Full Text] [PDF]